Anti-N Cadherin antibody [EPR1791-4] (Ab76011)
CD325, CDHN, NCAD, CDH2, Cadherin-2, CDw325, Neural cadherin, N-cadherin
详细信息
背景信息
Product Specifications Anti-N Cadherin antibody [EPR1791-4] (ab76011) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, WB in human, mouse, rat samples. Anti-N Cadherin antibody [EPR1791-4] (ab76011) specifically detects N Cadherin (UniProt ID: P19022; Molecular weight: 82kDa) and is sold in 100 µL and 1 mL selling sizes. Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-N Cadherin antibody [EPR1791-4] (ab76011) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-N Cadherin antibody [EPR1791-4] (ab76011) has been confirmed by testing in knockout samples. Anti-N Cadherin antibody [EPR1791-4] (ab76011) has been cited over 379 times in peer reviewed journals and is trusted by the scientific community. Anti-N Cadherin antibody [EPR1791-4] (ab76011) has 13 independent reviews from customers. Related Products Antibody clone EPR1791-4 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 488, Alexa Fluor® 594, Alexa Fluor® 568, Alexa Fluor® 555, Alexa Fluor® 750 ( ab195186, ab311055, ab311836, ab313119, ab313312, ab321710 ). Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (667)
METTL3-mediated m(6)A modification of CACNA1E promotes osteosarcoma progression and chemoresistance by enhancing WNT7B-mediated Ca(2+) signaling.
METTL3 介导的 CACNA1E 的 m(6)A 修饰通过增强 WNT7B 介导的 Ca(2+) 信号传导促进骨肉瘤进展和化疗耐药性。
Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets.
靶向新型免疫检查点 KLRG1 可通过多种淋巴细胞亚群对癌症产生显著的治疗作用。
Suppression of ASNS expression by VHL-mediated ubiquitination hinders the progression of renal cell carcinoma through enhancing JUP expression and inhibiting PI3K-AKT and MAPK pathways.
VHL介导的泛素化抑制ASNS表达,通过增强JUP表达和抑制PI3K-AKT和MAPK通路,阻碍肾细胞癌的进展。
HSP90AA1 restrains clear cell renal cell carcinoma progression by promoting CADM1 expression and suppressing the PI3K-AKT pathway through interaction with FBXO7.
HSP90AA1 通过与 FBXO7 相互作用,促进 CADM1 表达并抑制 PI3K-AKT 通路,从而抑制透明细胞肾细胞癌的进展。
ECM remodeling-associated immune signatures and hub proteins: predictive markers and therapeutic targets for metastatic gastric cancer.
ECM重塑相关免疫特征和枢纽蛋白:转移性胃癌的预测标志物和治疗靶点。
Transient receptor potential canonical 3 is required for HPV-induced malignant transformation of cervical epithelial cells.
瞬时受体电位通道3是HPV诱导宫颈上皮细胞恶性转化的必要条件。
Integrated Analyses Identify CDH2 as a Hub Gene Associated with Cisplatin Resistance and Prognosis in Ovarian Cancer.
综合分析表明,CDH2 是与卵巢癌顺铂耐药性和预后相关的关键基因。
Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial-Mesenchymal Transition and the PI3K Signalling Pathway.
环阿斯特拉醇通过上皮-间质转化和PI3K信号通路抑制结直肠癌细胞转移。
DNASE1L3 Mediates Hepatocellular Carcinoma Tumor Growth and Organoid Models via the Wnt/β-Catenin Signaling Pathway.
DNASE1L3 通过 Wnt/β-catenin 信号通路介导肝细胞癌肿瘤生长和类器官模型。
Phase-targeting rapid cryofixation of the beating heart and histological analysis unveil contractile state-dependent sarcomere dynamics.
对跳动的心脏进行相位靶向快速冷冻固定和组织学分析,揭示了收缩状态依赖的肌节动力学。
- 1
- 2
- 3
- 4
- 5
- 6
- 67